Company Name:Seattle Genetics, Inc.
CEO: Clay B. Siegall

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.


Key numbers

Market Capitalization:29153838840
Shares Outstanding: 173102000
Float: 171056800
Next Earning Date:
TTm EPS: -1.8642
TTm Dividend Rate:
200 days moving average:128.93
50 days moving average: 164.55
One day percent Change: -2.85



2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,